MK-0812 is chemokine receptor CCR-2 antagonist

LY2510924 is an inhibitor of CXC chemokine receptor 4 (CXCR4), with potential antineoplastic activity.

LMD-A (CCR8 antagonist LMD-A) is a highly potent, small molecule antagonist of chemokine receptor CCR8 with EC50 of 2.5 nM.

IT1t is a potent CXCR4 antagonist; inhibits CXCL12/CXCR4 interaction with an IC50 of 2.1 nM.

INCB3344 is a novel, potent and selective small molecule antagonist of the mouse CCR2 receptor; inhibits the binding of CCL2 to mouse monocytes with nanomolar potency (IC50 = 10 nM).

CXCR2-IN-1 is a central nervous system penetrant CXCR2 antagonists with a pIC50 of 9.3.

CX 4338 (CX4338, CX-4338) is a potent, selective CXCR2 inhibitor that selectively inhibits CXCR2-mediated recruitment of β-arrestin-2 with IC50 of 6.3 uM.

CCX140 is a potent CCR2 antagonist.

CCR6 inhibitor 35 is a potent and selective CCR6 inhibitor with IC50 of 6.0 nM (hCCR6).

AZ10397767 is a potent, selective CXCR2 inhibitor that inhibits CXCL8 binding to CXCR2 with pIC50 of 9.0.

AZ084 (AZ-084) is a potent, selective, allosteric, orally available CCR8 antagonist with Ki of 0.9 nM.

A small-molecule partial agonist of CXCR7 (ACKR3)..

A small-molecule partial agonist of CXCR7 (ACKR3)..

A small-molecule partial agonist of CXCR7 (ACKR3)..

A small molecule CMKLR1 antagonist that inhibits chemerin-stimulated β-arrestin2 association with CMKLR1 (EC50=9.7 nM).

A potent, specific, noncompetitive dual CXCR1 and CXCR2 antagonist with IC50 of 38 nM (vs. CXCL1) and 36 nM (vs. CXCL8), respectively.

A potent, specfic CXCR2 antagonist that inhibits IL8 down-regulation of forskolin-induced cAMP with IC50 of 7.79 uM.

A potent, selective, noncompetitive, orally active CCR2 antagonist with IC50 of 172 nM.

A potent, selective, allosteric CCR2 antagonist with IC50 of 103 nM..

A potent, selective, allosteric CCR2 antagonist with binding IC50 of 5.1 nM.

A potent, selective inhibitor of CXCL12 binding to CXCR4 and CXCR7 with IC50 of 200 nM.

A potent, selective and competitive CXCR2 inhibitor that selectively inhibits CXCR2-mediated recruitment of β-arrestin-2 with pKi of 8.92.

A potent, equipotent CXCR1 and CXCR2 antagonist with IC50 of 31 nM and 21 nM, respectively.

A potent CXCR7 (ACKR3) agonist..

A potent and orally bioavailable dual antagonist of CCR2 and CCR5 with binding IC50 of 0.7 nM and 2.4 nM, respectively.

A novel potent, selective CXCR2 inhibitor with IC50 of 7.6 nM.

A novel potent, selective CXCR2 inhibitor with IC50 of 0.4 nM.